Welcome to our dedicated page for Envveno Med SEC filings (Ticker: NVNBW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NVNBW SEC filings page on Stock Titan aggregates regulatory documents connected to ENVVENO MEDICAL CP WT 26 and its underlying issuer, enVVeno Medical Corporation. These filings, drawn from the SEC’s EDGAR system, include Forms 8-K, Definitive Proxy Statements on Schedule 14A, and references to shelf registration statements and prospectus supplements. Together, they provide a detailed record of how the company reports material events, stockholder actions, capital raising arrangements, and regulatory developments.
Form 8-K filings from 2025 illustrate several important themes. One 8-K dated October 10, 2025 discloses a Nasdaq notice that the company’s common stock no longer met the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market, and explains the 180-day compliance period, possible additional 180-day extension, and the potential role of a reverse stock split in curing the deficiency. Later 8-K filings dated December 12, 2025 report the results of the 2025 Annual Meeting of Stockholders, including director elections, an advisory vote on executive compensation, ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, the rejection of the 2025 Equity Incentive Plan, and stockholder authorization for the Board of Directors to implement a reverse stock split within a specified ratio range.
Another 8-K dated October 30, 2025 describes an At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc., under which the company may sell shares of its common stock from time to time as at-the-market equity offerings pursuant to an effective Form S-3 registration statement and a filed prospectus supplement. This filing also lists related exhibits, including the agreement itself and a legal opinion on the validity of the shares. An 8-K dated November 20, 2025 details an amendment to the company’s Amended and Restated Bylaws, revising the quorum requirement for stockholder meetings to a specified percentage of voting power, subject to applicable law and charter provisions.
Regulatory and product matters appear in an 8-K dated November 13, 2025, which reports that the company issued a press release about an unfavorable FDA appeal decision on its Premarket Approval application for VenoValve®, described as a surgical replacement venous valve for treating severe deep chronic venous insufficiency. The company notes that the press release is furnished as an exhibit, and the related Definitive Proxy Statement discusses a broader appeal process and its implications for both VenoValve and enVVe, a next generation transcatheter replacement venous valve.
On this NVNBW filings page, Stock Titan presents these documents with AI-powered summaries that help explain the significance of each filing. Investors can quickly see how stockholder votes affected equity incentive plans and reverse stock split authority, how the company structures at-the-market equity offerings, and how listing compliance issues and FDA-related outcomes are disclosed. The page also surfaces information relevant to monitoring governance practices, auditor relationships, bylaw changes, and other material events reported by enVVeno Medical Corporation in connection with the security associated with NVNBW.
enVVeno Medical Corp (NVNBW) filed a Form 144 notice reporting a proposed sale of 9,800 shares of common stock, acquired in an open market purchase on 12/31/2024. The filing lists the aggregate market value of the shares to be sold as $8,143.00 and shows 19,247,141 shares outstanding. The approximate date of sale is stated as 09/15/2025 and the broker named is The Charles Schwab Corporation, with the trade to occur on NASDAQ. The filer certifies they are not aware of any undisclosed material adverse information and indicates no securities were sold by the filer in the past three months.